Exclusive Megan Molteni From fusion to retooling cancer trials, Eric Lander wants his new group to ‘go after big problems’
Exclusive Jason Mast STAT Plus: Early findings in gene therapy death suggest CRISPR was not the cause
Exclusive Adam Feuerstein and Jason Mast STAT Plus: FDA staff leaned toward rejecting Sarepta gene therapy before top official intervened
Exclusive Shraddha Chakradhar and Casey Ross The history of OxyContin, told through unsealed Purdue documents
Special Report Sheila Kaplan To help cancer patients, lawmakers pushed access to a controversial doctor
Exclusive Casey Ross STAT Plus: Google will let health care customers test its generative AI model, ramping up rivalry with GPT-4
Exclusive Nicholas Florko New document reveals scope and structure of Operation Warp Speed and underscores vast military involvement
Exclusive Damian Garde Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine
Exclusive Rachel Cohrs and John Wilkerson STAT Plus: Senate hashing out policy details on generics, PBMs, insulin
Exclusive Rachel Cohrs, John Wilkerson and Ed Silverman STAT Plus: Sanders plans to haul in insulin executives to testify in Senate
Exclusive Jonathan Wosen STAT Plus: ‘It was my call’: Stanford president defends decision not to correct key paper in misconduct investigation
Exclusive Ed Silverman STAT Plus: FDA report details problems at Global Pharma plant involved in eye drop recall
Exclusive Adam Feuerstein and Damian Garde STAT Plus: Biogen’s Samantha Budd Haeberlein, an architect of Aduhelm, leaves company
Exclusive Kate Zernike STAT Plus: How Eric Lander’s sharp elbows spurred MIT’s Nancy Hopkins to start a gender revolution
Exclusive John Wilkerson STAT Plus: Senators probe telehealth companies for tracking and monetizing sensitive health data
Exclusive Sarah Owermohle STAT Plus: HHS’ Becerra on enrolling in Medicare, annual Covid vaccines, and seniors’ mental health
Exclusive Jason Mast STAT Plus: Calico looking for new chief scientist after celebrated biologist David Botstein quietly retires
Exclusive Matthew Herper and Casey Ross STAT Plus: Verily leans into Onduo as it looks to enter the lucrative world of running medical research
Health Tech Matthew Herper STAT Plus: Top Verily executives depart amid leadership shakeup and layoffs
Exclusive Jason Mast STAT Plus: Day One says drug shrinks tumors in common pediatric brain cancer, setting up potential approval
Exclusive Megan Molteni STAT Plus: Eric Lander’s next act: leading a nonprofit set on solving thorny scientific challenges
Exclusive Theresa Gaffney STAT Plus: Backed by a longtime mental health leader, a new startup aims to build support for serious mental illness
Exclusive Katie Palmer STAT Plus: Thirty Madison, looking to stand out in a crowded telehealth market, quietly plans expansion into sleep care
Exclusive Matthew Herper, Adam Feuerstein and Jason Mast STAT Plus: Biogen’s new CEO, clear-eyed about company’s challenges, prepares to take the reins
A STAT Investigation Jason Mast STAT Plus: Death of patient in closely watched Alzheimer’s trial raises concern about risk for some groups
Exclusive Rachel Cohrs STAT Plus: Inside Michelle McMurry-Heath’s departure from BIO: Firings, internal clashes, and a pivotal job review
Exclusive Mario Aguilar STAT Plus: Large insurer’s decision to cover some prescription digital therapies may be a milestone for app makers
Exclusive Matthew Herper, Adam Feuerstein and Damian Garde STAT Plus: Biogen CEO search focuses on scientists, with former J&J exec as a leading candidate
Exclusive Rachel Cohrs STAT Plus: Medicare tasks a senior adviser with staffing its new drug pricing division
Exclusive Mario Aguilar STAT Plus: Alzheimer’s clinical trials have a recruitment problem. Telehealth platform Ro thinks it can help